Condition
Crohn's disease news across medications, symptoms, tests, procedures, complications, research, access, and daily life.
Page 6 of 33 · 1547 articles
Imaging can reveal characteristic bowel and vascular patterns that help distinguish Crohn's, UC, celiac disease, and systemic autoimmune or vasculitic causes of GI symptoms, which may speed diagnosis and detect dangerous...
People with Crohn’s disease who need a repeat ileocolic resection may wonder whether laparoscopic surgery is a good option. This study suggests laparoscopic attempts are often successful, and if conversion is needed...
Predicting who will respond to anti-TNF drugs could help avoid ineffective treatments, reduce delays to effective therapy, and personalize care for children with Crohn's disease.
This study examines whether patterns of body size from birth through adulthood add information about IBD risk beyond adult BMI and genetic susceptibility. Results suggest life-course size trajectories may be more related...
This study suggests people with IBD have lower morning cortisol and a blunted cortisol awakening response, patterns that may be linked to systemic inflammation.
People with IBD face higher rates of anxiety, depression and other psychiatric disorders that often begin years before diagnosis and can persist long term. Recognizing and treating mental-health issues early can improve...
Bowel wall vascularization on ultrasound is used to gauge transmural inflammation in Crohn’s disease. This study examines whether quantitative measures could make those assessments more objective and how technique and...
Anti‑TNF drugs are a mainstay of IBD treatment. Understanding that they act through several immune mechanisms (not only neutralizing soluble TNF‑α) helps explain differences in effectiveness and informs conversations...
Virtual care reduced long-distance travel for IBD patients in remote Ontario, which both improves access to specialty care and appears to meaningfully lower travel-related CO2 emissions. Patients and clinics interested...
Patients and clinicians may care because the study suggests contrast-enhanced CT can reliably detect and localize IBD, including transmural and small-bowel disease that biopsies miss, which could affect diagnostic...
Handheld IUS could make noninvasive bowel assessment faster and more accessible for people with IBD, helping with triage and short-term monitoring without immediately resorting to endoscopy or advanced imaging.
If validated, metabolite patterns could help predict which children will reach remission on vedolizumab, potentially guiding treatment choices and avoiding ineffective therapy.
People with IBD face higher osteoporosis risk; this study looked for a genetic variant (LCT-13910C>T) that might affect bone density but found no clear link in this cohort, so it does not change current bone-health...
Patients with Crohn's who develop intra-abdominal abscesses often face decisions about antibiotics, drainage, or surgery. Predictors like abscess size and imaging appearance may help estimate the chance of needing...
The review links specific therapies and surgical options to outcomes that matter to people with IBD — mucosal healing, lower hospitalizations, and reduced need for surgery — and highlights that combining medical and...
Sarcopenia or low muscle mass may be linked with worse endoscopic healing and reduced durability of biologic therapy in IBD, particularly Crohn's disease, which could matter for prognosis and treatment planning if...
Mirikizumab is being tested specifically in children with moderate-to-severe Crohn’s disease; successful results could expand treatment options for pediatric IBD. The study measures both symptom-based and endoscopic...
This trial is testing whether continued mirikizumab treatment helps children and teens with ulcerative colitis or Crohn’s disease achieve and maintain remission over the long term. Results could expand pediatric...
Real-world PSP registries can show how long people stay on vedolizumab and how it’s used alongside or compared with other advanced therapies like tofacitinib. That information can help patients and clinicians understand...
People with IBD who have no or few symptoms but still have moderate–severe inflammation on endoscopy face uncertainty about whether to switch therapies to aim for endoscopic remission.
The study suggests blood metabolite patterns differ by biologic therapy and identifies candidate biomarkers that might help develop less-invasive monitoring tools for inflammation and treatment effects in Crohn’s...
Respiratory viral infections can be more serious in immunosuppressed patients. This study suggests systemic steroids (prednisolone) — but not biologics or immunomodulators in this dataset — were linked to higher...
If you had biologic treatment before bowel surgery, this study suggests restarting the same class of biologic after ileocolonic resection may prevent postoperative recurrence as well as switching to a new class — and may...
Crohn's-like disease of the pouch is a meaningful complication after IPAA that can impair quality of life and risk pouch failure; knowing which drug classes show promise for specific pouch phenotypes can guide...
Researchers and clinicians are increasingly studying combinations of IBD drugs because single‑drug remission rates have plateaued; dual therapy may improve outcomes for patients who have failed prior treatments.
Intestinal fibrosis causes strictures and surgery in many people with Crohn's disease; new RNA-based antifibrotic strategies delivered by nanocarriers could offer non-surgical treatment options in the future if they can...
Psychiatric disorders (especially depression, anxiety, and substance misuse) are more common in people with IBD starting a few years before diagnosis and remaining higher for years after. Recognizing this link can help...
Measuring mucosal healing across the whole gut with stool markers, ultrasound, and capsule endoscopy may give a clearer picture of whether biologic treatment is working and help guide decisions about continuing or...
Surgery remains an important treatment option for Crohn’s disease and may be considered earlier for some patients. Decisions about timing, technique, and perioperative care can affect long-term outcomes and recurrence...
Fibrosis causes strictures and surgery in many people with Crohn’s disease; a new immune pathway linked to fibrosis could point to future treatments. This study shows that γδ T cells and CD73-mediated adenosine signaling...
This study analyzes thousands of adverse event reports for ustekinumab in Crohn’s disease and highlights infections plus possible cardiovascular and neuropsychiatric signals that clinicians and patients may want to...
Many people with Crohn’s disease have ongoing inflammation despite stable medication. If dietary personalization can reduce inflammation, it could offer a nonpharmacologic add-on to help bridge gaps without immediate...
Most people with IBD can have children safely with modern treatments and planning; uncontrolled disease poses greater risks to pregnancy than continuing most IBD medications. Planning and specialist input before...
Researchers identified a specific immune receptor pathway (Dectin-1–CARD9) that senses a yeast species enriched in Crohn disease ulcers, suggesting a possible microbial trigger of inflammation relevant to IBD...
Researchers and clinicians looking for blood- or tissue-based molecular tests for IBD may find these integrated transcriptomic analyses useful because they identify candidate diagnostic biomarkers and highlight shared...
Oral signs such as persistent lip swelling can be an early presentation of Crohn’s disease in adolescents and may prompt testing that leads to earlier diagnosis and treatment.
The analysis suggests that placebo arms in Phase 3 IBD trials are associated with higher rates of serious events, mainly disease exacerbations; this matters because it raises ethical and safety concerns for people with...
If validated in clinical studies, extending the interval between subcutaneous vedolizumab doses could reduce injection frequency, costs, and treatment burden for some patients on maintenance therapy.
CVID can cause GI problems that closely mimic Crohn’s disease, ulcerative colitis, or celiac disease and may change diagnostic and treatment choices. Gastroenterologists need to consider CVID when IBD presentations are...
A new Phase 2 trial is testing whether intravenous allogeneic HB-adMSCs can improve Crohn’s symptoms and intestinal inflammation. If effective and safe, the therapy could offer a different mechanism of treatment from...
Patients on anti-TNF biologics often seek safe ways to support gut microbial health. This trial tests a prebiotic supplement (2'-FL) for safety and whether it increases beneficial bacteria and butyrate in young people...
People with Crohn’s disease who are overweight or have obesity may have different disease and treatment needs. This Phase 3 trial is testing whether adding tirzepatide to mirikizumab improves both disease outcomes and...
Cure8 could only read part of this source from health.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Symptoms and flares.
Mental health problems often begin before IBD is diagnosed and stay higher for years after; addressing psychiatric symptoms early could improve overall disease management and quality of life for people with Crohn’s...
A genetic marker (HLA-DRB1*01:03) was linked to more severe IBD outcomes—higher rates of colectomy/colonic surgery, more perianal disease, earlier use and higher failure of advanced therapies—which could help explain...
People with Crohn’s disease on ustekinumab may be more likely to need intensified dosing if they previously tried biologics or immunomodulators or have had disease longer; this could affect monitoring and planning. For...
Depression and suicide are important concerns for people with IBD. This study shows higher hospitalization risk for depression in IBD but a decline in those hospitalizations over time, which may reflect changing care...
The study suggests people with Crohn's disease or ulcerative colitis have higher lipoprotein(a) levels than healthy controls, which could be relevant because Lp(a) is a cardiovascular-risk biomarker and cardiovascular...
